Managed Entry AgreementMEA, Access-with-Evidence Agreement
An arrangement governing the conditions under which a technology enters the market, often incorporating outcomes-based payment or coverage with evidence development.
Terms for how medicine prices are set and negotiated and how patients gain access to new treatments.
An arrangement governing the conditions under which a technology enters the market, often incorporating outcomes-based payment or coverage with evidence development.
The overall process by which a manufacturer secures favourable coverage, reimbursement, and clinical adoption for a new health technology.
A manufacturer's overall plan for achieving favourable coverage, reimbursement, and clinical adoption for a new treatment, integrating pricing and evidence generation.
A period during which regulators will not approve a competing generic or biosimilar, arising from patent protection, regulatory provisions, or both.